Potential side effects of currently available pharmacotherapies in male lower urinary tract symptoms suggestive of benign prostatic hyperplasia

Müderrisoglu A. E., de la Rosette J. J. M. C. H., Michel M. C.

EXPERT OPINION ON DRUG SAFETY, vol.22, no.12, pp.1213-1224, 2023 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Review
  • Volume: 22 Issue: 12
  • Publication Date: 2023
  • Doi Number: 10.1080/14740338.2023.2293206
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.1213-1224
  • Keywords: Adverse event, benign prostatic hyperplasia, alpha 1-adrenoceptor antagonist, 5 alpha-reductase inhibitor, phosphodiesterase type 5 inhibitor, muscarinic antagonist, beta 3-adrenoceptor agonist, combination treatment
  • Istanbul Medipol University Affiliated: Yes


Introduction: The drug classes of α1-adrenoceptor antagonists, 5α-reductase inhibitors, and phosphodiesterase type 5 inhibitors are guideline-recommended treatments of lower urinary tract symptoms suggestive of benign prostatic hyperplasia; muscarinic receptor antagonists and β3-adrenoceptor agonists are also recommended if storage symptoms are insufficiently addressed with one of the other three drug classes. Areas covered: We provide a narrative review (no formalized literature searches performed) of the tolerability of these drug classes with emphasis on the more recently introduced medications, on combination treatment, and on more lately emerging risks. Expert opinion/commentary: The tolerability profiles are distinct between drug classes but, with few exceptions, similar within a drug class. Within a drug, formulations with longer duration of action tend to have better tolerability. Efficacy gains using combination treatment at least partly come at a cost of lesser tolerability. Greater susceptibility to experience adverse events based on age, comorbidities, and comedications appears conceptually important but remains under-investigated in this therapeutic area.